jurnalul român de psihofarmacologie romanian journal of ...

More documents

Recommendations

Info

253. Siegfried SL, Fleischhacker WW, Lieberman J. Pharmacological treatment of schizophrenia. In: Comprehensive care of schizophrenia, Eds Lieberman JJA, Murray RM, Martin Dunitz 2001:59-94. 254. Kapur S, Zipursky R, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156:2286-2293. 255. Geddes J, Freemantle N, Harrison P, Bebbicton P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Brit J Med 2000; 321:1371-1376. 256. Huber G, Gross G, Schuttler R, Linz M. Longitudinal studies of schizophrenic patients. Schizophr Bull 1980; 6:4592-605. 257. Marneros A, Dreister A, Rohde A. Psychopathological and social status of patients with affective, schizophrenic and schizoaffective disorders after long-term course. Acta Psychiatr Scand 1990; 82:352-8. 258. Health Care Reform for Americans with Severe Mental Illness: Report of the National Advisory mental Health Council. Am J Psychiatry 1993; 150:1447-1465. 259. Helgason L. Twenty years’ follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatr Scand 1990; 81:231-235. 260. Davis JM, Casper R. Antipsychotic drugs: clinical pharmacology and therapeutical use. Drugs 1977; 14:260-282. 261. Yazici KM, Erbas T, Yazici AH. The effect of clozapine on glucose metabolism. Exp Clin Endocrinol Diabetes 1998; 106:475-477. 262. Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter double blind olanzapine trial. Psychiatr Clin Neurosci 2001; 55:403-414. 263. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999; 45:403-411. 264. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, Miller AL. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002; 53:239-248. 265. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001; 26:137-149. 153
266. Barnas C, Stuppaeck CH, Miller C, Haring C, Sperner-Unterweger B, Fleischhacker WW. Zotepine in the treatment of schizophrenic patients with prevailing negative symptoms. A double blind trial vs haloperidol. Int Clin Psychopharmacol 1992; 7:23-27. 267. Muller-Spahn F, Dieterle D, Ackerheil M. Clinical effectiveness of zotepine in treatment of negative schizophrenic symptoms. Results of an open and double-blind controlled trial. Fortschr Neurol Psychiatr 1991; 59(Suppl. 1):30-35. 268. Wighton A, Tweed JA, Butler A, Welch CP, Reynolds C, Bratty JR. The efficacy of zotepine in treating negative symptoms of schizophrenia: the results of a meta-analysis. Int J psychiatr Clin Practice 2000; 4:209-214. 154
Page 1 and 2:
Vol. 3, Nr. 3, 4 2003 JURNALUL ROM
Page 3 and 4:
A R P F Romanian Journal of Psychop
Page 5 and 6:
EVALUATION DES MEDICAMENTS DANS LE
Page 7 and 8:
Enfin dans le cadre de l’épisode
Page 9 and 10:
cas ou un tel médicament serait é
Page 11 and 12:
ECHELLE C.G.I. (Clinical Global Imp
Page 13 and 14:
12. Frank E, Kupfer DJ, Gerebtzoff
Page 15 and 16:
Pour définir les critères d'inclu
Page 17 and 18:
ESTE JUSTIFICATĂ INTERVENŢIA TERA
Page 19 and 20:
pacienţii care au avut o durată m
Page 21 and 22:
7. Loebel A.D., Lieberman J.A, Alvi
Page 23 and 24:
determină creşterea concentraţie
Page 25 and 26:
special de disfuncţia noradrenergi
Page 27 and 28:
PSIHOFARMACOLOGIA CLINICĂ A TERAPI
Page 29 and 30:
apare la un interval de timp bine d
Page 31 and 32:
c) Studiul Zürich (Jules Angst, 19
Page 33 and 34:
mai cu seamă a terapiilor combinat
Page 35 and 36:
Descoperirea în ordine cronologic
Page 37 and 38:
Succesiunea de etape istorico-crono
Page 39 and 40:
prurigo, etc) interpretate diagnost
Page 41 and 42:
Antidepresivele de generaţia a pat
Page 43 and 44:
Bibliografie 1. Frank E, Prien RF,
Page 45 and 46:
TERAPIA BIOLOGICĂ A DEPRESIILOR I.
Page 47 and 48:
Indicaţia primară a Carbamazepine
Page 49 and 50:
3. Currier, B. M., Murray, G. & Wel
Page 51 and 52:
În cursul tratamentului pot interv
Page 53 and 54:
Aplicând scala MADRS la pacienţii
Page 55 and 56:
Proprietăţile antihistaminice H1
Page 57 and 58:
Utilizarea antihistaminicelor H1 ne
Page 59 and 60:
s-a dovedit într-un studiu multice
Page 61 and 62:
În plus, depresia este corelată c
Page 63 and 64:
21. Juhlin, L., 1981 - Recurrent ur
Page 65 and 66:
DEPRESIA ŞI EPILEPSIA G. Bădescu,
Page 67 and 68:
Rolul GABA în depresie - un defici
Page 69 and 70:
menţionează 25 % simptome psihiat
Page 71 and 72:
10. Kanner, A.M., Palac, S., 2000 -
Page 73 and 74:
De la descoperirea primului antidep
Page 75 and 76:
Tratamentul de lungă durată cu am
Page 77 and 78:
Tachikininele produc fenomenul de
Page 79 and 80:
Hiperactivitatea locomotorie şi mo
Page 81 and 82:
Efectele secundare în sfera sexual
Page 83 and 84:
15. Saria A., 1999 - The tachykinin
Page 85 and 86:
Termenul de neuropsihoendocrinologi
Page 87 and 88:
Atât pacienţii depresivi cât şi
Page 89 and 90:
Bibliografie selectivă 1. Agid, O.
Page 91 and 92:
TRATAMENTUL CU SERTRALINĂ ÎN TULB
Page 93 and 94:
În cel de-al doilea lot, a existat
Page 95 and 96:
EFECTUL SEDATIV ŞI ALTERAREA PERFO
Page 97 and 98:
La doze terapeutice, clorfeniramina
Page 99 and 100:
arierei hematoencefalice de către
Page 101 and 102:
decât pentru loratadină, fără d
Page 103 and 104:
viteză de 95 km/h, reprezintă o c
Page 105 and 106:
6. Hindmarch, I., Shamsi, Z., 1999
Page 107 and 108: 35. Tashiro, M., Mochizuki, H., Iwa
Page 109 and 110: În insuficienţa hepatică cronic
Page 111 and 112: În hiperamoniemia moderată cronic
Page 113 and 114: c. GABA (acid gamma aminobutiric) e
Page 115 and 116: Iată deci cum factori diferiţi, c
Page 117 and 118: Perspectiva psihosocială Buss - 19
Page 119 and 120: În sindromul Kluver-Bucy (ablaţia
Page 121 and 122: Bibliografie selectivă 1. Allen, T
Page 123 and 124: International Journal for Postgradu
Page 125 and 126: familia pacientului, formularea pla
Page 127 and 128: Participarea familiei trebuie să i
Page 129 and 130: VI. Antipsihoticele convenţionale:
Page 131 and 132: Chiar dacă toate aceste medicament
Page 133 and 134: ezistenţi la tratament (19, 35, 36
Page 135 and 136: În studiile controlate în alte tu
Page 137 and 138: Ib. Iloperidona Iloperidona este un
Page 139 and 140: 9. American Psychiatric Association
Page 141 and 142: 42. Casey DE. Side effects profiles
Page 143 and 144: 67. von Fischer-Cornelssen K, Ferne
Page 145 and 146: 93. Klieser E, Lehmann E, Kinzler E
Page 147 and 148: 121. Beasley Jr CM, Hamilton SH, Cr
Page 149 and 150: schizophrenia presenting psychotic
Page 151 and 152: 168. Segal J, Berk M, Brook S. Risp
Page 153 and 154: 192. Hale AS. A review of the safet
Page 155 and 156: 215. Hori M, Suzuki M, Shiraishu H,
Page 157: 240. Honigfeld G, Patin J. A two-ye
Page 161 and 162: I. Strategii de comunicare 1. COMUN
Page 163 and 164: 2.2 Recomandări Profesioniştii as
Page 165 and 166: 4.2 Recomandări � Cel puţin în
Page 167 and 168: � Trebuie elaborate şi larg dist
Page 169 and 170: schizofrenie nu au „personalită
Page 171 and 172: instituţionalizări (18). Cu toate
Page 173 and 174: 9. Revicki DA. Pharmacoeconomic eva
Page 175: Instructions to authors The text mu
show all

jurnalul român de psihofarmacologie romanian journal of ...

Create successful ePaper yourself

Delete template?

Save as template?